Trial Profile
Follow-up of Study C87040: Multicentre, Double-blind Study to Describe the Efficacy and Safety of Re-treatment With CDP870 (Certolizumab Pegol) Subcutaneous at 2 Different Dose Regimens (400 mg Initial Dose at Week 0 With 200 mg Every 2 Weeks Thereafter and 400 mg Every 2 Weeks) or Placebo for 12 Weeks, in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy and/or Phototherapy and/or Photochemotherapy, Having Responded to Treatment in Study C87040 and Having Subsequently Relapsed
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 May 2019
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors UCB
- 25 Jun 2014 New trial record